KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Average (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Equity Average data on record, last reported at $559.4 million in Q3 2025.

  • For Q3 2025, Equity Average rose 25.04% year-over-year to $559.4 million; the TTM value through Sep 2025 reached $559.4 million, up 25.04%, while the annual FY2024 figure was $566.0 million, 44.42% down from the prior year.
  • Equity Average reached $559.4 million in Q3 2025 per EBS's latest filing, up from $544.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.6 billion in Q1 2022 and bottomed at $447.4 million in Q3 2024.
  • Average Equity Average over 5 years is $1.1 billion, with a median of $1.3 billion recorded in 2023.
  • Peak YoY movement for Equity Average: soared 37.28% in 2021, then tumbled 51.42% in 2024.
  • A 5-year view of Equity Average shows it stood at $1.6 billion in 2021, then dropped by 9.48% to $1.4 billion in 2022, then decreased by 23.8% to $1.1 billion in 2023, then crashed by 54.15% to $495.6 million in 2024, then increased by 12.86% to $559.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $559.4 million in Q3 2025, $544.4 million in Q2 2025, and $517.8 million in Q1 2025.